Antibody evasion by a gammaherpesvirus O-glycan shield

PLoS Pathogens

Volumn 7, Issue 11, 2011, Pages

  Machiels, Bénédicte ^a   Lété, Céline ^a   Guillaume, Antoine ^a   Mast, Jan ^b   Stevenson, Philip G ^c   Vanderplasschen, Alain ^a   Gillet, Laurent ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b VETERINARY AND AGROCHEMICAL RESEARCH CENTRE   (Belgium)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; EPITOPE; GLYCOPROTEIN; GLYCOPROTEIN GP 180; GLYCOPROTEIN GP 350; GREEN FLUORESCENT PROTEIN; HETERODIMER; LECTIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; MEMBRANE PROTEIN;

ANIMAL CELL; ANTIGENICITY; ARTICLE; BLOOD SAMPLING; BOVINE HERPESVIRUS 4; CONTROLLED STUDY; FLOW CYTOMETRY; GLYCOSYLATION; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION SENSITIVITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION MAPPING; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SOUTHERN BLOTTING; VIRION; VIRUS ATTENUATION; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS LATENCY; VIRUS NEUTRALIZATION; VIRUS REPLICATION; AMINO ACID SEQUENCE; ANIMAL; GENETICS; IMMUNOLOGY; MOLECULAR GENETICS; PHYSIOLOGY; RABBIT; SEQUENCE ALIGNMENT; SERODIAGNOSIS;

BOVINE HERPESVIRUS 4; HUMAN HERPESVIRUS 4;

AMINO ACID SEQUENCE; ANIMALS; EPITOPES; GLYCOSYLATION; HERPESVIRUS 4, BOVINE; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; RABBITS; SEQUENCE ALIGNMENT; VIRAL ENVELOPE PROTEINS; VIRION; VIRUS REPLICATION;

EID: 81755177711     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002387     Document Type: Article

References (89)

1. Thorley-Lawson DA, Gross A, (2004) Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350: 1328-1337.
2. Verma SC, Robertson ES, (2003) Molecular biology and pathogenesis of Kaposi sarcoma-associated herpesvirus. FEMS Microbiol Lett 222: 155-163.
3. Salvetti M, Giovannoni G, Aloisi F, (2009) Epstein-Barr virus and multiple sclerosis. Curr Opin Neurol 22: 201-206.
4. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, et al. (2007) Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 204: 2899-2912.
5. Hadinoto V, Shapiro M, Sun CC, Thorley-Lawson DA, (2009) The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog 5: e1000496.
6. Niederman JC, Miller G, Pearson HA, Pagano JS, Dowaliby JM, (1976) Infectious mononucleosis. Epstein-Barr-virus shedding in saliva and the oropharynx. N Engl J Med 294: 1355-1359.
7. Yao QY, Rickinson AB, Epstein MA, (1985) A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer 35: 35-42.
8. Desgranges C, de-The G, (1978) Presence of Epstein-Barr virus specific IgA in saliva of nasopharyngeal carcinoma patients: their activity, origin and possible clinical value. IARC Sci Publ pp. 459-469.
9. Sarid O, Anson O, Yaari A, Margalith M, (2001) Epstein-Barr virus specific salivary antibodies as related to stress caused by examinations. J Med Virol 64: 149-156.
10. Buisman AM, Abbink F, Schepp RM, Sonsma JA, Herremans T, et al. (2008) Preexisting poliovirus-specific IgA in the circulation correlates with protection against virus excretion in the elderly. J Infect Dis 197: 698-706.
11. Ogra PL, Karzon DT, Righthand F, MacGillivray M, (1968) Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. N Engl J Med 279: 893-900.
12. Burton DR, (2002) Antibodies, viruses and vaccines. Nat Rev Immunol 2: 706-713.
13. Heldwein EE, Krummenacher C, (2008) Entry of herpesviruses into mammalian cells. Cell Mol Life Sci 65: 1653-1668.
14. Chandran B, (2010) Early events in Kaposi's sarcoma-associated herpesvirus infection of target cells. J Virol 84: 2188-2199.
15. Hutt-Fletcher LM, (2007) Epstein-Barr virus entry. J Virol 81: 7825-7832.
16. Pertel PE, (2002) Human herpesvirus 8 glycoprotein B (gB), gH, and gL can mediate cell fusion. J Virol 76: 4390-4400.
17. Miller N, Hutt-Fletcher LM, (1988) A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus. J Virol 62: 2366-2372.
18. Gill MB, Gillet L, Colaco S, May JS, de Lima BD, et al. (2006) Murine gammaherpesvirus-68 glycoprotein H-glycoprotein L complex is a major target for neutralizing monoclonal antibodies. J Gen Virol 87: 1465-1475.
19. Gillet L, Gill MB, Colaco S, Smith CM, Stevenson PG, (2006) Murine gammaherpesvirus-68 glycoprotein B presents a difficult neutralization target to monoclonal antibodies derived from infected mice. J Gen Virol 87: 3515-3527.
20. Gillet L, May JS, Colaco S, Stevenson PG, (2007) The murine gammaherpesvirus-68 gp150 acts as an immunogenic decoy to limit virion neutralization. PLoS One 2: e705.
21. Nemerow GR, Mold C, Schwend VK, Tollefson V, Cooper NR, (1987) Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J Virol 61: 1416-1420.
22. Tanner J, Weis J, Fearon D, Whang Y, Kieff E, (1987) Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell 50: 203-213.
23. Thorley-Lawson DA, Poodry CA, (1982) Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J Virol 43: 730-736.
24. Janz A, Oezel M, Kurzeder C, Mautner J, Pich D, et al. (2000) Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands. J Virol 74: 10142-10152.
25. Shannon-Lowe CD, Neuhierl B, Baldwin G, Rickinson AB, Delecluse HJ, (2006) Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells. Proc Natl Acad Sci U S A 103: 7065-7070.
26. Turk SM, Jiang R, Chesnokova LS, Hutt-Fletcher LM, (2006) Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells. J Virol 80: 9628-9633.
27. Sokal EM, Hoppenbrouwers K, Vandermeulen C, Moutschen M, Leonard P, et al. (2007) Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 196: 1749-1753.
28. Cox C, Naylor BA, Mackett M, Arrand JR, Griffin BE, et al. (1998) Immunization of common marmosets with Epstein-Barr virus (EBV) envelope glycoprotein gp340: effect on viral shedding following EBV challenge. J Med Virol 55: 255-261.
29. Nash AA, Dutia BM, Stewart JP, Davison AJ, (2001) Natural history of murine gamma-herpesvirus infection. Philos Trans R Soc Lond B Biol Sci 356: 569-579.
30. Gillet L, Daix V, Donofrio G, Wagner M, Koszinowski UH, et al. (2005) Development of bovine herpesvirus 4 as an expression vector using bacterial artificial chromosome cloning. J Gen Virol 86: 907-917.
31. Zimmermann W, Broll H, Ehlers B, Buhk HJ, Rosenthal A, et al. (2001) Genome sequence of bovine herpesvirus 4, a bovine Rhadinovirus, and identification of an origin of DNA replication. J Virol 75: 1186-1194.
32. de Lima BD, May JS, Stevenson PG, (2004) Murine gammaherpesvirus 68 lacking gp150 shows defective virion release but establishes normal latency in vivo. J Virol 78: 5103-5112.
33. Machiels B, Lete C, de Fays K, Mast J, Dewals B, et al. (2010) Bovine Herpesvirus-4 Bo10 gene encodes a non-essential viral envelope protein that regulates viral tropism through both positive and negative effects. J Virol 85: 1011-1024.
34. Dewals B, Thirion M, Markine-Goriaynoff N, Gillet L, de Fays K, et al. (2006) Evolution of Bovine herpesvirus 4: recombination and transmission between African buffalo and cattle. J Gen Virol 87: 1509-1519.
35. Shin YC, Jones LR, Manrique J, Lauer W, Carville A, et al. (2010) Glycoprotein gene sequence variation in rhesus monkey rhadinovirus. Virology 400: 175-186.
36. Dunowska M, Letchworth GJ, Collins JK, DeMartini JC, (2001) Ovine herpesvirus-2 glycoprotein B sequences from tissues of ruminant malignant catarrhal fever cases and healthy sheep are highly conserved. J Gen Virol 82: 2785-2790.
37. Julenius K, Molgaard A, Gupta R, Brunak S, (2005) Prediction, conservation analysis, and structural characterization of mammalian mucin-type O-glycosylation sites. Glycobiology 15: 153-164.
38. Maley F, Trimble RB, Tarentino AL, Plummer TH Jr, (1989) Characterization of glycoproteins and their associated oligosaccharides through the use of endoglycosidases. Anal Biochem 180: 195-204.
39. Skehel JJ, Stevens DJ, Daniels RS, Douglas AR, Knossow M, et al. (1984) A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci U S A 81: 1779-1783.
40. Aguilar HC, Matreyek KA, Filone CM, Hashimi ST, Levroney EL, et al. (2006) N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J Virol 80: 4878-4889.
41. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
42. Gillet L, Stevenson PG, (2007) Evidence for a multiprotein gamma-2 herpesvirus entry complex. J Virol 81: 13082-13091.
43. Lomonte P, Filee P, Lyaku JR, Bublot M, Pastoret PP, et al. (1997) Glycoprotein B of bovine herpesvirus 4 is a major component of the virion, unlike that of two other gammaherpesviruses, Epstein-Barr virus and murine gammaherpesvirus 68. J Virol 71: 3332-3335.
44. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, et al. (2002) The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-&2 mannose residues on the outer face of gp120. J Virol 76: 7306-7321.
45. Galili U, Clark MR, Shohet SB, Buehler J, Macher BA, (1987) Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1----3Gal epitope in primates. Proc Natl Acad Sci U S A 84: 1369-1373.
46. Machiels B, Gillet L, Nascimento Brito SD, Drion P, Delforge C, et al. (2007) Natural antibody-complement dependent neutralization of bovine herpesvirus 4 by human serum. Microbes Infect 9: 1530-1537.
47. Lavine JS, Poss M, Grenfell BT, (2008) Directly transmitted viral diseases: modeling the dynamics of transmission. Trends Microbiol 16: 165-172.
48. Villarreal LP, Defilippis VR, Gottlieb KA, (2000) Acute and persistent viral life strategies and their relationship to emerging diseases. Virology 272: 1-6.
49. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL, (2000) Viral subversion of the immune system. Annu Rev Immunol 18: 861-926.
50. Yewdell JW, Hill AB, (2002) Viral interference with antigen presentation. Nat Immunol 3: 1019-1025.
51. Stevenson PG, Simas JP, Efstathiou S, (2009) Immune control of mammalian gamma-herpesviruses: lessons from murid herpesvirus-4. J Gen Virol 90: 2317-2330.
52. Hoffman GJ, Lazarowitz SG, Hayward SD, (1980) Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci U S A 77: 2979-2983.
53. Miller G, Heston L, Hoffman G, (1982) Neutralization of lymphocyte immortalization by different strains of Epstein-Barr virus with a murine monoclonal antibody. Infect Immun 37: 1028-1031.
54. Sashihara J, Burbelo PD, Savoldo B, Pierson TC, Cohen JI, (2009) Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. Virology 391: 249-256.
55. Moutschen M, Leonard P, Sokal EM, Smets F, Haumont M, et al. (2007) Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 25: 4697-4705.
56. Miller G, Niederman JC, Stitt DA, (1972) Infectious mononucleosis: appearance of neutralizing antibody to Epstein-Barr virus measured by inhibition of formation of lymphoblastoid cell lines. J Infect Dis 125: 403-406.
57. Rosa GT, Gillet L, Smith CM, de Lima BD, Stevenson PG, (2007) IgG fc receptors provide an alternative infection route for murine gamma-herpesvirus-68. PLoS One 2: e560.
58. Chandran B, Smith MS, Koelle DM, Corey L, Horvat R, et al. (1998) Reactivities of human sera with human herpesvirus-8-infected BCBL-1 cells and identification of HHV-8-specific proteins and glycoproteins and the encoding cDNAs. Virology 243: 208-217.
59. Szakonyi G, Klein MG, Hannan JP, Young KA, Ma RZ, et al. (2006) Structure of the Epstein-Barr virus major envelope glycoprotein. Nat Struct Mol Biol 13: 996-1001.
60. Johnson WE, Desrosiers RC, (2002) Viral persistence: HIV's strategies of immune system evasion. Annu Rev Med 53: 499-518.
61. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861.
62. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, et al. (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329: 811-817.
63. Lee JE, Saphire EO, (2009) Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. Curr Opin Struct Biol 19: 408-417.
64. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, et al. (2008) Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454: 177-182.
65. Back NK, Smit L, De Jong JJ, Keulen W, Schutten M, et al. (1994) An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 199: 431-438.
66. Reitter JN, Means RE, Desrosiers RC, (1998) A role for carbohydrates in immune evasion in AIDS. Nat Med 4: 679-684.
67. Li Y, Cleveland B, Klots I, Travis B, Richardson BA, et al. (2008) Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol 82: 638-651.
68. Pantophlet R, Burton DR, (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24: 739-769.
69. Yang X, Kurteva S, Lee S, Sodroski J, (2005) Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. J Virol 79: 3500-3508.
70. Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, et al. (2007) The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1: 135-145.
71. Gillet L, Stevenson PG, (2007) Antibody evasion by the N terminus of murid herpesvirus-4 glycoprotein B. EMBO J 26: 5131-5142.
72. Helle F, Vieyres G, Elkrief L, Popescu CI, Wychowski C, et al. (2010) Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol 84: 11905-11915.
73. Dubuisson J, Guillaume J, Boulanger D, Thiry E, Bublot M, et al. (1990) Neutralization of bovine herpesvirus type 4 by pairs of monoclonal antibodies raised against two glycoproteins and identification of antigenic determinants involved in neutralization. J Gen Virol 71 (Pt 3): 647-653.
74. Biller M, Mardberg K, Hassan H, Clausen H, Bolmstedt A, et al. (2000) Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties. Glycobiology 10: 1259-1269.
75. Doores KJ, Fulton Z, Hong V, Patel MK, Scanlan CN, et al. (2010) A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity. Proc Natl Acad Sci U S A 107: 17107-17112.
76. Vanderplasschen A, Markine-Goriaynoff N, Lomonte P, Suzuki M, Hiraoka N, et al. (2000) A multipotential beta-1,6-N-acetylglucosaminyl-transferase is encoded by bovine herpesvirus type 4. Proc Natl Acad Sci U S A 97: 5756-5761.
77. Balzarini J, (2007) Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat Rev Microbiol 5: 583-597.
78. Balzarini J, (2005) Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV. Lancet Infect Dis 5: 726-731.
79. Astronomo RD, Burton DR, (2010) Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov 9: 308-324.
80. Donofrio G, van Santen VL, (2001) A bovine macrophage cell line supports bovine herpesvirus-4 persistent infection. J Gen Virol 82: 1181-1185.
81. Huynh HT, Robitaille G, Turner JD, (1991) Establishment of bovine mammary epithelial cells (MAC-T): an in vitro model for bovine lactation. Exp Cell Res 197: 191-199.
82. Gillet L, Schroeder H, Mast J, Thirion M, Renauld JC, et al. (2009) Anchoring tick salivary anti-complement proteins IRAC I and IRAC II to membrane increases their immunogenicity. Vet Res 40: 51.
83. Thiry E, Pastoret PP, Dessy-Doizé C, Hanzen C, Calberg-Bacq CM, (1981) Herpesvirus in infertile bull's testicle. Vet rec 108: 426.
84. Dubuisson J, Thiry E, Bublot M, Sneyers M, Boulanger D, et al. (1989) Production and characterization of monoclonal antibodies to bovid herpesvirus-4. Vet Microbiol 19: 305-315.
85. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG, (2005) Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res 33: e36.
86. Dewals B, Boudry C, Farnir F, Drion PV, Vanderplasschen A, (2008) Malignant catarrhal fever induced by alcelaphine herpesvirus 1 is associated with proliferation of CD8+ T cells supporting a latent infection. PLoS ONE 3: e1627.
87. Boudry C, Markine-Goriaynoff N, Delforge C, Springael JY, de Leval L, et al. (2007) The A5 gene of alcelaphine herpesvirus 1 encodes a constitutively active G-protein-coupled receptor that is non-essential for the induction of malignant catarrhal fever in rabbits. J Gen Virol 88: 3224-3233.
88. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG, (1997) The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25: 4876-4882.
89. Bendtsen JD, Nielsen H, von Heijne G, Brunak S, (2004) Improved prediction of signal peptides: SignalP 3.0. J Mol Biol 340: 783-795.